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Medical Statistics) and actual drug prices (Rote Liste,
2003) were used to calculate total costs of CSA treatment
in Germany from the German payers perspective for the
year 2003. (Discounts from the whole saler, pharmaceu-
tical industry, retail pharmacies and patients copayments
were taken into consideration). RESULTS: Total efﬁcacy
as stated by the physicians depends on CSEA and was
seen between 53% and 76%. The total efﬁcacy experi-
enced by the physicians weighted with 2002 sales was
71%. Total sales in 2003 are €995.6 million. In total €1.4
billion must be invested for completely (100%) reaching
the LDL-C goal of the European treatment guideline.
CONCLUSION: Although it is stated by Klose and
Schwabe (2003) that nearly €2.million of estimated €2.8
million patients could be treated sufﬁciently with CSEA
the results of our study indicate that the investment for a
sufﬁcient treatment must be higher or the treatment itself
must be improved by more efﬁcient drugs.
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OBJECTIVES: To evaluate the total treatment cost 
and cost-effectiveness of three alternative treatments for
patients with acute myocardial infarction from the per-
spective of the Greek NHS. METHODS: A systematic
review of the literature was conducted to identify RCTs
evaluating the treatments considered. Outcomes include
all major health events associated with an AMI. Trial data
we extracted and used to populate a decision analytic
model. Data from long term studies were used to extrap-
olate 30-day and one-year data to end of lifetime. The
model also accounts for patient risk croup, in regards to
age, sex, time-to- treatment, etc. The database of a large
University Hospital was analyzed to estimate in-patient
and outpatient costs associated with various groups of
patients. Simulation was used to test the robustness of the
results. RESULTS: Outcome data primarily come from
GUSTO III and ASSENT 2 and their follow ups. For the
average patient life time costs on alteplase, reteplase 
and tenecteplase were similar, at €24,205, €24,308, and
€24,488 respectively. Average survival was 8.2221,
8.2110, and 8.2919 years respectively. Tenecteplase has
marginally higher cost and outcomes. Alteplase and ten-
ecteplase dominate the second arm and the incremental-
cost-per-life-year-saved of tenecteplase over alteplase is
about €4000, and for that reason it should be preferred
on the basis of its very cost-effective ratio. These results
are based the point estimates and in general terms they
also hold true when simulation is employed. CONCLU-
SIONS: The cost of the original treatment is only a minor
component of the total life time treatment cost of AMI
patients. The treatments evaluated here have similar sur-
vival and different health event proﬁles, but despite that
they are characterized by similar total treatment costs, so
that it is difﬁcult to distinguish between them. If anything,
tenecteplase is characterized by a marginally better cost-
effectiveness ratio.
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OBJECTIVES: Statin therapy reduces the rate of coro-
nary heart disease (CHD), but high costs in combination
with a large population eligible for treatment ask for pri-
oritizing. One of the tools of priority setting is cost-
effectiveness analysis (CEA). Even though all trials agree
on the size of the beneﬁt, CEA of statins report contra-
dictory results. We reviewed CEA comparing statins with
no pharmacological therapy and sought to synthesize cost
effectiveness ratios (CER) for categories of risk of CHD
and age. The level of heterogeneity among CER and its
potential sources were evaluated. METHODS: Systematic
review of the published statin CEA in Medline, the British
National Health Service Economic Evaluation database
and authors’ reference lists. Outcomes were standardized
by inﬂation and currency and stratiﬁed by risk and age.
CER under US$20,000 per life year saved were “cheap”,
over US$40,000 were “expensive” and in between were
“moderate”. Sources of heterogeneity in the outcomes
after stratiﬁcation were analyzed using a regression
model. RESULTS: Twenty-four studies were included,
yielding 216 CER. The range of CER varied 10-fold
(savings to $489,394). Disagreement existed at levels of
risk lower than 4%. After adjusting for risk in the regres-
sion model, the only signiﬁcant variable was funding
source. CONCLUSIONS: Statin therapy is cheap for high
levels of risk, but discrepancies exist at lower levels.
Scarce evidence exists for younger and older ages (<45,
>65). Competing interests between pharmaceutical com-
panies wanting to sell more and governments wanting to
spend less may have strong impact on the results. Clear
guidelines for CEA could reduce their vulnerability to bias
and assure reproducibility.
PCV69
THE COST-EFFECTIVENESS OF CYP2C9
GENOTYPING IN MANAGEMENT OF WARFARIN
THERAPY—A DECISION TREE ANAYSIS
You JH, Chan FW, Cheng G
The Chinese University of Hong Kong, Hong Kong, China
670 Abstracts
OBJECTIVES: To evaluate the cost-effectiveness of
CYP2C9 genotyping for the management of anticoagula-
tion therapy in patients newly started on warfarin from
the provider’s perspective. METHODS: A decision tree
was designed to simulate, over 12 months, the outcomes
of patients newly started on warfarin associated with two
alternatives: 1) no genotyping (standard care group); and
2) CYP2C9 genotyping prior to initiation of warfarin
therapy (genotyping group). Each alternative could lead
to three possible outcomes: No event, bleeding, and
thromboembolic event (TE). Patients in the standard care
group would receive standard care of the anticoagulation
clinic (AC). In the genotyping group, intensiﬁed antico-
agulation service would be provided to patients with at
least one variant CYP2C9 allele while others would
receive standard AC care. The intensiﬁed AC service was
assumed to reduce all event rates by 50% and cost more
than standard service by 50%. The prevalence of
CYP2C9 polymorphism and event rates was derived from
literature. Cost of standard AC service and manage-
ment of events were estimated from the literature and the
Diagnosis-Related Groups charges. Sensitivity analysis
was conducted to examine the robustness of the model.
RESULTS: The cost per patient-year and event-free rate
per 100 patient-year of the genotyping group and the
standard care group were USD 1729 and 89%, and, USD
2068 and 85%, respectively. One-way sensitivity analysis
showed that the model was sensitive to variation of two
variables: rate of bleeding in patients with at least one
variant CYP2C9 allele (threshold value = 0.04 events per
100 patient-year) and the reduction of bleeding rate in
patients with at least one variant CYP2C9 allele with the
intensiﬁed service (threshold value = 10%). CONCLU-
SION: The genotyping group was less expensive and
more effective than the standard care group for the man-
agement of anticoagulation therapy in patients newly
started on warfarin.
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OBJECTIVE: To conduct an economic evaluation of
unfractionated heparin (UFH) compared with low mole-
cular weight heparin (LMWH) enoxaparin in acute 
coronary syndrome (ACS) treatment. METHODS: Two
group patients with ACS. Arm A: 23 patients with 
unstable angina (UA)—52.2% and non-Q-wave myocar-
dial infarction (NQWMI)—37.8% treated by UFH, 200
IU/kg/day. Arm B:—23 patients, 52.2% in UA and 37.8%
in NQWMI treated by enoxaparin 1mg/kg/twice a day.
All patients were treated by heparin up to remission
achievement. Economic evaluation was done by cost—
effectiveness analysis usage. The costs of the treatment
and resource utilization items were analyzed. Unit costs
were based on detailed data from the Moscow Obliga-
tory Insurance Fond (January 2003). The total direct
medical costs were calculated as a sum of costs for
follows: expenses on medicine and drug using, hospital
expenditures, diagnostic and laboratory tests, time allo-
cation. Achievement of stable remission of the process
was the effectiveness. RESULTS: The total direct medical
costs of Arm A came to 538,960 rubles and expenditures
for heparin usage were 10,000 rubles (1.8%) of them.
And for Arm B it was 457,072 rubles as total medical
costs and 53,146 rubles or 11.6% of them for enoxaparin
usage. Stable remission was 65% and 83% for Arms A
and B respectively. Serious side effects weren’t registered
at all. Cost effectiveness (CE) index for both groups was
calculated as CE = The total costs of whole treatment/
Effectiveness (% of remission) CE A = 360.5 rubles/% 
per patient. CE B = 239.43 rubles/% per patient. The 
Rate of Exchange was 31.5 rubles for USD$1. CON-
CLUSION: in spite of the high costs for LMWH in
compare to UFH this is evidence based way for approach-
ing necessary effect of patients in ACS with investment
saving.
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OBJECTIVES: To evaluate the total treatment cost and
cost-effectiveness of treatments for elderly patients with
acute myocardial infarction and patients for which treat-
ment starts later, in the Greek NHS. METHODS: Data
are coming from large RCTs evaluating the treatments
considered. Outcomes include all major health events
associated with an AMI. Trial data we extracted and used
to populate a decision analytic model that computes
events rates, survival and costs from AMI occurance till
death. The model reports results for patients above 75
and for patients for which treatments starts at least 4
hours after symptom onset. The database of a large Uni-
versity Hospital was analyzed to estimate in-patient and
outpatient costs associated with various events. Simula-
tion was used to test the robustness of the results.
RESULTS: For patients above 75 life time costs on
alteplase, reteplase and tenecteplase were estimated, at
€13.485, €13.400, and €13.824 respectively. Average sur-
vival was 1.8396, 1.8039, and 1.9325 years respectively.
Tenecteplase has marginally higher cost and outcomes.
Alteplase and tenecteplase dominate the second arm and
